-
Global Biotechnology & Pharmaceutical Markets1 month agoNovo turns to Hengrui for another oral obesity drug
Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once...
-
Drug Discovery & Therapeutics1 month agoAZ takes stake in Summit Therapeutics in $2bn deal
AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.
-
Regulatory Intelligence & Drug Approvals1 month agoFDA clears first drug for MCT8 deficiency
Sweden's Egetis has won approval in the US for the first-ever treatment for people living with the ultra-rare genetic disease MCT8 deficiency.
-
Drug Discovery & Therapeutics1 month agoTest could end uncertainty in inherited muscle diseases
A new study suggests long-read 'nanopore' sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.
-
Regulatory Intelligence & Drug Approvals1 month agoAbbVie’s Cerevel takeover delivers Parkinson’s approval
The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.
-
Regulatory Intelligence & Drug Approvals1 month agoMSD, Daiichi pull filing for lung cancer candidate I-DXd
MSD and Daiichi Sankyo's regulatory efforts for their ADCs for cancer have stuttered again, with a withdrawn filing for lung cancer candidate I-DXd.
-
Regulatory Intelligence & Drug Approvals1 month agoEU clears first drug therapy for rare disease cALD
Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
-
Regulatory Intelligence & Drug Approvals1 month agoFDA starts speedy review of Imfinzi in bladder cancer
AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.
-
Regulatory Intelligence & Drug Approvals1 month agoFDA nominee Overton dodges questions on Trump influence
Trump's FDA nominee Heidi Overton was quizzed on a range of issues at her Senate hearing, including vaccines, the abortion pill, and agency reforms.
-
Clinical Trials & Development1 month agoWnt drug gives MSD first eye disease win after EyeBio deal
MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
